Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ricardo reiterates opposition to Science Group, backs chair

(Sharecast News) - Ricardo insisted it was making "good progress" on Friday, as it reiterated its opposition to moves by shareholder Science Group to overhaul the board. AIM-listed Science Group has built up a 16.2% stake in the environmental and engineering consultancy, and wants chair Mark Clare to step down.

It has previously threatened to requisition a general meeting if its proposed board changes do not go ahead.

However, on Friday Ricardo reiterated that the board continued to "fully support and have confidence" in Clare.

In particular, it argued that Science Group wanted to replace Clare with its own executive chair, which would give the company "effective control of the board without paying for that control".

It continued: "The board believes that Science Group's actions are being taken solely for the benefit of Science Group and its own shareholders, and are contrary to the interests of Ricardo's other shareholders.

"Accordingly, the board has informed Science Group that, having met to consider its demand that the chair be replaced, the remaining non-executive directors have resolve to unanimously reject it."

Ricardo said it was making "good progress" in its portfolio transformation, first announced in 2022, which has seen the company's shift from mobility services to environmental and energy transitions.

Ricardo saw profits and its share price fall sharply over the last year, after the large number of elections in 2024 and mounting geopolitical uncertainty delayed energy transition agendas.

However, it said on Friday it was trading in line with expectations, with both the order book and underlying operating profits up in the first half.

It also announced a business and strategy update for mid-April to "ensure that is shareholders have a full understanding of that actions that are being undertaken to driven performance".

Science Group has yet to comment.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.